Evidence map›Paper›PMID 29131533›Full record

Trial reportCancer medicine2017

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).

Hiroshi Ishiguro, Shigehira Saji, Shogo Nomura, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Hiroji Iwata, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi

Open access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Hiroshi IshiguroDepartment of Medical Oncology, International University of Health and Welfare Hospital, Nasushiobara, Japan.ORCID http://orcid.org/0000-0002-9859-5932
Shigehira SajiDepartment of Medical Oncology, Fukushima Medical University, Fukushima, Japan.
Shogo NomuraCenter for Research and Administration and Support, National Cancer Center, Kashiwa, Japan.
Sunao TanakaDepartment of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takayuki UenoDepartment of Breast Surgery, Kyorin University Hospital, Mitaka, Japan.
Masahide OnoueDepartment of Pharmacy, Kitano Hospital, Osaka, Japan.
Hiroji IwataDepartment of Breast Oncology, Aichi Cancer Center, Nagoya, Japan.
Takeharu YamanakaDepartment of Biostatistics, Yokohama City University, Yokohama, Japan.
Yasutsuna SasakiDepartment of Medical Oncology, Showa University, Tokyo, Japan.
Masakazu ToiDepartment of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University · JPAichi Cancer Center · JPFukushima Medical University · JPInternational University of Health and Welfare · JPKitano Hospital · JPKyorin University Hospital · JPNational Cancer Center Hospital East · JPShowa University · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

S-1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor receptor 2 (HER2)-negative breast cancer previously treated with anthracyclines and taxanes were eligible. Patients with brain metastases and homozygous for UGT1A1 *6 or *28 or compound heterozygous (*6/*28) were excluded. A dose-escalation design was chosen for the phase I portion (level 1: irinotecan 80 mg/m

Indexed as

Neoplasm Recurrence, LocalPharmacogenomic VariantsAdultAgedAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCamptothecinDisease-Free SurvivalDrug Administration ScheduleDrug CombinationsEndothelial Progenitor CellsFemaleGene FrequencyGlucuronosyltransferaseHeterozygoteAntigens, CD34CamptothecinDrug CombinationsGlucuronosyltransferaseIrinotecanOxonic AcidS 1 (combination)TegafurUGT1A1 EnzymeBreast Cancercirculating endothelial cellsIrinotecanS-1SN-38UGT1A1

Identifiers

PMID29131533
PMCPMC5727322
OpenAlexW2770450554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.